Astellas Canada was also featured on list of Best Workplaces™ for Inclusion in 2019 Astellas Pharma Canada is proud to announce that today the company was named to the 2020 List of Best Workplaces™ for Inclusion by the Great Place to Work® Institute, the second year in a row that for the organization has received this award. "We're very pleased to be recognized by Great Place to Work for our...

XOSPATA is the first and only targeted treatment approved by Health Canada for patients with relapsed or refractory Acute Myeloid Leukemia with a FLT3 mutation. The approval of XOSPATA marks Astellas’ Canadian entry into the treatment of blood cancers. MARKHAM, ON, Jan.14, 2020 /CNW/ - Astellas Pharma Canada, Inc., announced that Health Canada has approved the oral once-daily therapy XOSPATA...

Award is a first for Astellas and comes in addition to recognition previously received in six Great Place to Work ® categories Markham, ON - December 2, 2019 - Astellas Pharma Canada, Inc. (Astellas; Astellas Canada), the Canadian subsidiary of Tokyo-based Astellas Pharma, Inc., has been honoured as the winner of the Business Employer of Excellence Award by the Markham Board of Trade. "Astellas...

Astellas employees contributed more than 455 volunteer hours to support Variety Village On October 21st, Astellas Pharma Canada employees had the opportunity to step away from their desks, roll up their sleeves, and spend the day volunteering during Changing Tomorrow Day, the company’s annual global day of service. Changing Tomorrow Day is a series of company-sponsored volunteer events for...

- Canadian tops list of four innovators awarded $200,000 in total grants and resources following live pitch event to a panel of judges that included celebrity entrepreneur Bill Rancic - NORTHBROOK, Ill., Oct. 28, 2019 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") today announced it has awarded $200,000 in total grants and resources to winners of the fourth annual C 3 (Changing Cancer Care)...